Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D. DiNardo, Hagop M. Kantarjian, Nicholas J. Short et al.|Journal of Clinical Oncology|2021Cited by 333
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Abhishek Maiti et al.|The Lancet Haematology|2020Cited by 330
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i> -Mutated Myeloid MalignanciesCurtis A. Lachowiez, Courtney D. DiNardo, Sanam Loghavi et al.|Blood Cancer Discovery|2023Cited by 122
Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First RemissionAlexandre Bazinet, Tapan M. Kadia, Naval Daver et al.|Blood|2024Cited by 4